ARB

DRUG6 trials

Sponsors

National Taiwan University Hospital, Boehringer Ingelheim, Yonsei University, Uppsala University, Consorci Sanitari de Terrassa

Conditions

ACE InhibitorsARBAmantadineAntihistamine AllergyCOVIDCOVID19Chronic Renal FailureHypertension

Phase 4

Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)

National Taiwan University HospitalChronic Renal Failure

Start: 2010-06-30End: 2018-12-31Target: 350Updated: 2016-10-14

Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy

Yonsei UniversityIgA Nephropathy

Start: 2016-06-30End: 2018-10-31Target: 100Updated: 2016-12-05

Randomized Evaluation of Beta Blocker and ACEI/ARB Treatment in MINOCA Patients - MINOCA-BAT

TerminatedNCT03686696

Uppsala UniversityMyocardial Infarction With Non-obstructive Coronary Arteries

Start: 2018-12-16End: 2023-08-22Updated: 2023-11-27

Unknown Phase

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

CompletedNCT02215733

Boehringer IngelheimNeoplasm

Start: 2011-02-28Updated: 2014-08-13

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

RecruitingNCT04367883

Consorci Sanitari de TerrassaACE Inhibitors, Amantadine, Antihistamine Allergy +3

Start: 2020-03-01End: 2028-02-24Target: 3000Updated: 2026-03-25

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

CompletedNCT04467931

University of UtahCOVID, Hypertension

Start: 2020-01-19End: 2020-12-31Updated: 2021-04-28

Related Papers

Clinical study outcomes in IgA nephropathy: A systematic literature review and narrative synthesis.

2025-06-101 citations